Department of General Surgery, Peking University Third Hospital, Beijing, 100191, China.
Int J Med Sci. 2021 Jan 1;18(3):801-810. doi: 10.7150/ijms.49576. eCollection 2021.
Risk assessment has high prognostic value in patients with colorectal cancer (CRC), and the use of proper models is an effective approach frequently used to evaluate cancer progression for further treatment plans. Alterations in metabolism are confirmed to be a significant feature of tumor cells and have been an intense focus in disease research. Here, we mined the genes that were differentially expressed in CRC tissues compared to paired normal samples from a public database and then constructed a novel assessment system for the prognosis of patients based on the value of a risk score considering the expression status of metabolism-related genes after screening. The score successfully stratified patients by risk and was externally verified in our study. Moreover, we built a nomogram combining the score and clinical parameters to predict patient survival using a visual method. The results suggested that the risk score was well fit and could provide assistance for the individual treatment of CRC patients in the clinic.
风险评估对结直肠癌（CRC）患者具有较高的预后价值，而使用适当的模型是评估癌症进展以制定进一步治疗计划的有效方法。代谢改变被证实是肿瘤细胞的一个重要特征，也是疾病研究的一个热点。在这里，我们从公共数据库中挖掘了与配对正常样本相比在 CRC 组织中差异表达的基因，然后构建了一个基于风险评分的新型评估系统，该评分考虑了代谢相关基因的表达状态，用于筛选后的患者预后评估。该评分成功地根据风险对患者进行了分层，并在我们的研究中进行了外部验证。此外，我们还构建了一个列线图，将评分和临床参数结合起来，通过可视化方法预测患者的生存情况。结果表明，该风险评分拟合良好，可以为临床中 CRC 患者的个体化治疗提供帮助。
